Safety issues with fentanyl patches require pharmaceutical care

Canadian Journal of Hospital Pharmacy

Volumn 61, Issue 1, 2008, Pages 57-59

  Greenall, Julie ^a   Koczmara, Christine ^a   Cheng, Roger ^a   Hlyland, Sylvia ^a  

^a Institut pour l'utilisation securitaire des medicaments du Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL DEPRESSANT AGENT; CLARITHROMYCIN; CODEINE; DIHYDROMORPHINE; DILTIAZEM; ERYTHROMYCIN; FENTANYL; KETOCONAZOLE; KETOROLAC; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ARTICLE; BACKACHE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; COMORBIDITY; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG SAFETY; FATALITY; LEG PAIN; PAIN; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHARMACIST;

EID: 40349093486     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Picard A. Coroner investigates high-risk painkiller. Globe and Mail [Toronto] 2007 Sep 5 [cited 2007 Nov 21]. Available from: http://www.theglobeandmail.com/servlet/story/RTGAM.20070905.wlpatch05/ BNStory/specialScienceandHealth/home
2. Fentanyl patch linked to another death in Canada. ISMP Can Saf Bull 2007[cited 2007 Nov 21];7(5):1-2. Available from: http://www.ismp-canada.org/download/ISMPCSB2007-05Fentanyl.pdf
3. Transdermal fentanyl: a misunderstood dosage form. ISMP Can Saf Bull 2006[cited 2007 Nov 21];6(5):1-2. Available from: http://www.ismp-canada.org/download/ISMPCSB2006-05Fentanyl.pdf
4. Ongoing, preventable fatal events with fentanyl transdermal patches are alarming! ISMP Med Saf Alert 2007[cited 2007 Nov 21];12(13):1-4. Available from: http://www.ismp.org/Newsletters/acutecare/articles/ 20070628.asp
5. Institute for Safe Medication Practices. Little patches ... big problems. New safety warnings about fentanyl patches - Part 1. ISMP Med Saf Alert Community/Ambulatory Ed 2005;4(8):1-3.
6. Health Canada, Health Products and Food Branch, Marketed Health Products Directorate. Transdermal fentanyl (Duragesic): respiratory arrest in adolescents. Can Adverse React Newsl 2004[cited 2007 Nov 21];14(4):1-2. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/ bulletin/carn-bcei_v14n4_e.html
7. Health Canada endorsed important safety information on Duragesic (fentanyl transdermal system). Ottawa (ON): Health Canada; 2005 Sep 16 [cited 2007 Dec 19]. Available from: http://www.hc-sc.gc.ca/dhp-mps/ medeff/advisories-avis/prof/2005/duragesic_hpc-cps_e.html
8. Avoiding fatal overdoses with fentanyl patches. FDA Patient Safety News. Rockville (MD): Food and Drug Administration; 2005 [cited 2007 Nov 21]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/ transcript.cfm?show=44#2 (includes video webcast).
9. Duragesic fentanyl transdermal system. Janssen-Ortho; 2007 Mar 30 [cited 2007 Nov 21]. Available from: http://www.janssen-ortho.com/JOI/pdf_files/ Duragesic_E.pdf
10. Seki J, Turner L. Medication safety alerts: development of equianalgesic charts. Can J Hosp Pharm 2006;59(3):152-153.